SEP 4, 2026 · PHASE 3 TRIAL
A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)
ClinicalTrials.gov
This is a registered Phase 3 trial that has not yet recruited or reported results; the registry entry describes only the planned design and primary outcome measure, with no efficacy or safety data available.
Reported
Planned enrollment180
Primary outcome measurePercent change from baseline in body weight
Assessment timepointWeek 72